Cervical cancer, primarily caused by high-risk human papillomavirus (HR-HPV) types 16
and 18, is a major global health concern. Persistent HR-HPV infection can progress from …

Background: Cervical dysplasia persistence/recurrence has a great impact on women's
health and quality of life. In this study, we investigated whether a prognostic nomogram may …

False negative (FN) results in cervical cancer (CC) screening pose serious risks to women.
We present a comprehensive literature review on the risks and reasons of obtaining the FN …

As the primary screening test, E6/E7 mRNA has shown similar sensitivity for CIN3+ and
lower positivity rate than the HPV DNA test. Nevertheless, the overall mRNA positivity is too …

Background Each high-risk HPV genotype has different oncogenic potential, and the risk of
CIN3+ varies according to genotype. We evaluated the performance of different strategies of …

Background: We evaluated the longitudinal performance of three options: HPV16/18
genotyping (HPV16/18), cytology (LBC), and p16/Ki-67 dual stain cytology (DS) for the triage …

Abstract The Polish Society of Colposcopy and Cervical Pathophysiology and the Polish
Society of Gynecologists and Obstetricians provide comprehensive guidelines for …

Background Immunocytochemical staining with p16/Ki67 has been suggested as a
promising triage biomarker in cervical cancer screening. As dual staining is a subjective …

How to manage human papillomavirus (HPV)‐positive women in cervical cancer screening
remains debated. Our study compared different strategies to triage HPV positivity in a large …

Background The objective of this study was to describe the determinants of adequacy and
positivity of the p16/Ki‐67 assay in a human papillomavirus (HPV)‐positive screening …